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In type 1 diabetes (T1D)  cell mass is markedly reduced by autoimmunity. Type 2 diabetes (T2D) results from
inadequate  cell mass and function that can no longer compensate for insulin resistance. The reduction of  cell
mass in T2D may result from increased cell death and/or inadequate birth through replication and neogenesis.
Reduction in mass allows glucose levels to rise, which places  cells in an unfamiliar hyperglycemic environment,
leading to marked changes in their phenotype and a dramatic loss of glucose-stimulated insulin secretion (GSIS),
which worsens as glucose levels climb. Toxic effects of glucose on  cells (glucotoxicity) appear to be the culprit.
This dysfunctional insulin secretion can be reversed when glucose levels are lowered by treatment, a ﬁnding with
therapeutic signiﬁcance. Restoration of  cell mass in both types of diabetes could be accomplished by either  cell
regeneration or transplantation. Learning more about the relationships between  cell mass, turnover, and function
and ﬁnding ways to restore  cell mass are among the most urgent priorities for diabetes research.
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Introduction
While type 1 diabetes (T1D) clearly results from a
loss of  cells, there were decades of uncertainty
about the contribution of  c e l lf a i l u r et ot y p e2
diabetes (T2D). In the ﬁrst half of the 20th century
it was generally assumed that  cell failure was im-
portant for all diabetes. In the 1960s, however, the
development of the insulin radioimmunoassay led
to the ﬁnding that plasma insulin levels were of-
ten high in T2D, leading many to assume that the
pathogenesis could be explained by insulin resis-
tance alone. However, over the past 15 years there
hasbeengeneralagreementthatcellinadequacyis
a fundamental part of T2D. The growing incidence
ofT2Disdrivenbyinsulinresistance,whichislikely
theresultofatypicalWesternlifestylecharacterized
by obesity and minimal exercise. A key point is that
most people with insulin resistance will never de-
velop T2D: diabetes only results if their  cells fail
to provide sufﬁcient insulin. This review will focus
upontherelationshipbetweencellmassandfunc-
tionindiabetes,andthecomplicatedissuesof cell
birth, death, and replenishment.
 cell mass
In a normal adult human pancreas,  cell mass is
approximately 2% of pancreatic weight. About one
millionisletsarescatteredthroughoutthepancreas,
which translates to roughly one billion  cells. Pan-
creases typically weigh between 60 g and 100 g, so 
cell mass is somewhere near 1–2 g.
In1955MacleanandOgilvie1 reported, in a care-
fulstudyonautopsypancreasesusinghistochemical
staining, that  cell mass in older people with di-
abetes (presumably mostly T2D) was about 50%
of controls, although this ﬁnding was largely ig-
nored. It was also found that  cell mass was not
altered. Similar estimates of  cell mass were found
in a few small studies, and then in 2003 a study
led by Butler and Butler reported similar ﬁnd-
ings using immunostaining in autopsy pancreases
from better-characterized subjects.2 There was
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Figure 1.  cell relative volume in autopsy pancreases from
individuals who were nondiabetic (ND) had impaired fasting
gl u c o s e( I F T G )o rh a dtype2d i a be t e sm e ll i t u s(TT D M ) .F i g u r e
takenfromRef.2,withpermissionfromtheAmericanDiabetes
Association.
considerable scatter in the data, but in both lean
and obese individuals the relative  cell volume, a
surrogate for mass, was about 30–70% of nondi-
abetic controls. Importantly, in subjects with im-
pairedfastingglucoselevels,the cellmasswasalso
reduced,butlessso,toabout60%ofnormal(Fig.1).
ThoroughstudiesfromKoreaandBelgiumreported
similarreductionsin cell mass in T2D.3,4 Another
ﬁnding important for understanding T2D is that
obesenondiabeticsubjectsinthreestudieshadonly
a 20–40% increase in  cell mass compared to lean
controls.2,4,5 Thisonlymodestincreasewassurpris-
ing,astheincreaseof cellmassininsulinresistant
mice is proportionally much higher.6
In T1D,  cells are decimated by autoimmunity
and the process usually occurs over several years.
There are few pathological studies and  cell imag-
inghasnotadvancedenoughtobehelpful,soouras-
sumptions are largely extrapolated from C-peptide
secretion and insulin requirements. Because some
individuals with new-onset T1D have remissions
that can last for several months, it is thought that
 cell mass at diagnosis might be as high as 50%
of normal in some individuals.7 We know from the
Diabetes Control and Complications Trial (DCCT)
thatC-peptidelevelscanbesubstantialinsomesub-
jects soon after diagnosis but then fall to negligible
levels in just a few years.8 A new remarkable ﬁnd-
ing is that  cells may never be completely wiped
outin T1D. The Joslin Medalist Study includes sub-
jectswhohavehadT1Dforover50years.9 In recent
yearsanumberofthemhavediedanddonatedtheir
pancreases for study. At this writing,  cells iden-
tiﬁed by insulin immunostaining have been found
in all 28 subjects (S. Bonner-Weir, unpublished). It
also appears that those few with more residual C-
peptide have more  cells. The presence of these 
cellsraisesimportantquestionsastowhethercells
havespecialcharacteristicsthatresistdestructionor
whethernewcellsarecontinuallyformedbyrepli-
cation of existing  cells and/or by neogenesis and
then destroyed by persisting autoimmunity.
The quest to measure  cell mass with
imaging
Accurate measurement of  cell mass in living sub-
jects would greatly enhance our understanding of
the pathogenesis of both T1D and T2D, as well as
the monogenic forms of diabetes, making it a ma-
jor research priority. For both types it would be of
great value to follow the dynamics of the decline in
 cellmassbecauseitmightbepossibletolinkthese
to pathogenetic mechanisms. In T1D this could be
enormouslyhelpfulinevaluatingtheefﬁcacyofvar-
ious immune interventions that are being tested in
subjectswithprediabetesandnew-onsetdiabetes.In
both types of diabetes we would very much like to
understand the effects of medication and glycemic
control on  cell mass.
Unfortunately, it has proved very difﬁcult to de-
velop any methods that come close to being accu-
rate. There was great interest in the type 2 vesic-
ular monoamine transporter (VMAT2), which is
expressed by  cells, can be labeled with [11C]-
dihydrotetrabenazine,andthenmeasuredwithPET
scanning.Unfortunately,inhumansubjectsthisap-
pears to be insufﬁciently speciﬁc.10 Now the GLP-1
receptor, which may be speciﬁc enough for  cells,
is receiving much attention.11 Another approach is
to tag inﬂammation in the pancreas of T1D, which
correlates with the activity of autoimmunity; the
ﬁrst published results in humans look promising.12
Most of the approaches to imaging  cells over the
pastseveralyearshavebeenrecentlyreviewed.13One
caveat is that to be useful a method will proba-
bly need to accurately measure differences in  cell
mass in the range of only 5%, because such small
changes are likely to make a difference in glycemic
control.
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Normal  cell function and maintenance of
mass
 cells have a remarkable ability to make and store
largequantitiesofinsulinandthensecretethisprod-
uct with exquisite timing and precision. Glucose is
the dominant factor controlling  cell function and
survival, and a unique glucose recognition mecha-
nism allows control by extracellular concentrations
of glucose that usually range between 4 mM and
8 mM (70–140 mg/dL). This is accomplished by
wide-open GLUT2 glucose transporters in rodents,
although probably more by GLUT1 in humans.14,15
These transporters allow the extracellular and in-
tracellular glucose concentrations to be essentially
the same. The key glucose signaling for insulin se-
cretion is done by glucose metabolism, the rate of
which is controlled by glucose phosphorylation by
glucokinase,withaKm ofabout7mM.16,17 Glucose
metabolism at the mitochondrial level turns on se-
cretionviathereasonablywell-understoodK+-ATP-
dependent pathway and the less well-understood
K+-ATP independent pathway.18 The  cell also re-
sponds to signals from the brain via both branches
of the autonomic nervous system19 and the in-
cretin hormones from the intestine, gastrointesti-
nal insulinotropic peptide (GIP),and glucagon-like
peptide 1 (GLP-1).20
The  cell provides very efﬁcient control of glu-
cose levels with eating as secreted insulin starts ac-
tivating the liver even before blood glucose levels
rise, due to vagal stimulation during the cephalic
phaseofinsulinsecretion17 andsecretionofincretin
hormones. As insulin secretion rises, glucagon se-
cretion is suppressed, allowing this increased in-
sulin/glucagon ratio to enhance hepatic glucose
uptake at just the right time.21 Protection against
hypoglycemia is particularly dependent upon rapid
shutdownofinsulinsecretionbyfallingglucoselev-
els.22 Thusglucoseandotherfactorscanturnonin-
sulin secretion within minutes and, when removed,
shut it off as quickly.
Oscillations of insulin secretion
Insulin secretion exhibits oscillation with a peri-
odicity of about ﬁve minutes,23,24 which appears
to be coordinated by intrapanceatic neural connec-
tions.25 Because these oscillations are so prominent
in the portal vein, they likely have important inﬂu-
ence on insulin’s effects upon the liver. Disruption
of these oscillations has been found in T2D,26 and
it could have a negative inﬂuence on hepatic insulin
action.
β cell hypertrophy and atrophy
Glucose appears to be dominant among the factors
inﬂuencingthemaintenanceofcellmass.Changes
i ng l u c o s el e v e l ss e e mt od r i v et h em a j o rd e t e r m i -
nants of  cell mass, hyperplasia, hypertrophy, and
atrophy. Chronic hypoglycemia, which occurs with
insulin-secreting tumors, leads to marked  cell at-
rophy,27 whereas chronic hyperglycemia can lead
to  cell hyperplasia and hypertrophy.28,29 Using
partial pancreatectomy to create a model of hyper-
glycemiainrats,wefoundthatindividual cell size
increasedby85%.29 Increasesinglucoselevelsstim-
ulate replication within a day,30 and over time lead
to hyperplasia. Glucose stimulation of  cell repli-
cation has also been found in an in vivo model of
glucose infusion in mice31 and an in vivo model of
human islet transplantation.32
Compensatory β cell response to insulin
resistance when blood glucose levels are
normal
There has been considerable debate about how 
cellsecretionandmasscanbeaugmentedininsulin
resistant states when increases in glucose levels can-
not be determined. We favor the view that because
glucose is such a dominant determinant of  cell
functionandgrowth,thesechangesaremainlycon-
trolled by extremely efﬁcient glucose feedback on 
cells.6,33,34 There may be subtle changes in glucose
levels that make a difference and there is evidence
of increased activity of glucokinase,35 which means
thata cellcanbemoreresponsiveatlowerglucose
concentrations. There is much interest in the pos-
sibility that some important signals are produced
by the liver because of the impressive  cell com-
pensation found with knockout of hepatic insulin
receptors in mice.34 The search continues.
Dysfunctional insulin secretion as
diabetes develops
When glucose levels chronically rise to levels only
modestly higher than normal, dramatic dysregula-
tion of insulin secretion appears. This was shown
most impressively with a simple experiment pub-
lished over 35 years ago (Fig. 2).36 Adult humans
withvariouslevelsoffastingglycemiareceivedrapid
infusions of glucose intravenously to elicit acute
glucose-simulated insulin secretion (GSIS). When
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Figure 2. IncrementsofacuteGSISinsubjectswithincreasing
fasting plasma glucose levels. Figure taken from Ref. 36, with
permission from the Endocrine Society.
the fasting glucose was normal at 4.5–5.6 mM
(80–100mg/dL)alargespikeofinsulinsecretionap-
pearedwithinjustafewminutes.However,themag-
nitude of GSIS was much lower when glucose levels
rose above 5.6 mM and by the time they reached
6.4 mM (115 mg/dL), a level in the range of im-
paired fasting glucose (IFG), acute GSIS, a predia-
beticstateequatedwithﬁrst-phaseinsulinsecretion,
was completely obliterated. Nonetheless, the  cells
functioned well enough to maintain the prediabetic
state because they can respond to more prolonged
glucosestimulationwithsecondphaserelease37 and
to acute stimulation by incretin signals such as
GLP-1, as well as amino acids. These ﬁndings have
now been reproduced in multiple human and ani-
mal studies.
Dysfunction of  cells becomes more serious as
the diabetic state worsens and functional mass de-
teriorates. A given  cell mass puts out less insulin
in response to stimuli. In another old study, sub-
jects with and without T2D received maximal 
cell stimulation from prolonged infusions of glu-
cose augmented with arginine.38 It can be assumed
that the  cell mass of these T2D subjects was in the
range of 50% of normal, yet their insulin response
to this maximal stimulus was only 15% of normal
(Fig. 3).
Importantly from a therapeutic perspective, the
severedysfunctioninducedbythediabetic statecan
be reversed if glucose levels are brought to normal,
as best shown by the full restoration of secretion
after bariatric surgery.39 It is surprising how little
we know about the timing of this restoration. In
T2D, partial improvement in GSIS was found after
a 20-hour infusion of insulin40 and changes after
gastric surgery were found weeks to months later.
This is an important question because a thorough
understanding of the timing and magnitude of the
effects of glucotoxity could have therapeutic value.
The case for the importance of
glucotoxicity and lack of importance
of lipotoxicity and glucolipotoxicity
While it is clear that the diabetic milieu is respon-
sible for  cell dysfunction, there has been much
discussion about the contributions of glucotoxicity,
lipotoxicity, and glucolipotoxicity.41–43 T h ec a s ef o r
thedominanceofglucotoxicitycanbemadebecause
of the remarkably tight correlation between glucose
levels and loss of acute GSIS. Moreover, changes in
insulin secretion after several days of glucose infu-
sions in rats resemble those seen in diabetics,44 yet
such infusions suppress free fatty acid (FFA) levels.
Also,similarlossofGSIScanbefoundwhenisolated
islets are exposed to high-glucose concentrations in
culture.45,46
The case for lipotoxicity is based almost entirely
upon in vitro exposure of primary  cells and  cell
linestoFFAsinculture,especiallythesaturatedFFA
palmitate.NotonlydoespalmitatedisruptGSISand
other types of insulin secretion, but also it has be-
come a favorite tool in the study of  cell death. It
is not at all clear that the FFA concentrations used
for these in vitro studies are similar to those seen by
 cells in vivo. We have little understanding of how
FFAs are handled in the interstitial space and the
environment of lipid membranes that surround 
cells.Ithasalsobeenpostulatedthatpalmitategiven
invitrotocellsmaybeconvertedtothetoxicprod-
uct tripalmitin, which is not expected to be formed
in vivo.47 An apparent shortcoming in the use of
FFAs or high glucose concentrations48 to study 
cell death is that the frequency of death in so many
in vitro studies is far higher than the frequency seen
invivo,whichraisesconcernsabouttherelevanceof
some of the mechanisms that have been identiﬁed.
There are a few in vivo studies using infusions of
lipid,49 but the resultant FFA levels are so high that
their clinical relevance must be questioned.
Data obtained from in vivo studies on lipotoxic-
ity in humans and animal models are also uncon-
vincing. For example, FFA levels are high in obe-
sity, which is associated with exuberant GSIS. The
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Figure 3. Subjects with noninsulin-dependent diabetes
(NIDDM, T2D) and control subjects whose glucose levels were
increased with glucose infusions followed by acute stimulation
ofinsulinsecretionwithintravenousarginine.Figuretakenfrom
Ref. 38, with permission from the Endocrine Society.
increase of glucose levels in prediabetes correlates
very precisely with GSIS dysfunction,36 but a simi-
larcorrelationwithFFAhasyettobedemonstrated.
Ithasalsobeenpostulatedthatincreasedlipidstores
in the form of droplets cause toxicity, but a correla-
tion between lipid stores and secretory dysfunction
in  cells has yet to be shown.50 Moreover,  cell se-
cretory dysfunction can be found in db/db mice in-
dependentofplasmalipidlevels.51TheobeseZucker
diabetic fatty (ZDF) rat model of diabetes has been
proposed as an example of lipotoxicity because the
late stage islets contain large quantities of lipid as
diabetes worsens.52 The problem is that it has never
been shown that most of this lipid is located in 
cells rather than the ﬁbroblasts and adipocytes that
can be seen in these anatomically distorted islets.
Proponents of lipotoxicity found that in vitro ex-
posure of  c e l l st oF F A sa n dh i g hg l u c o s ew a se v e n
more damaging, which led to the widely used term
glucolipotoxicity. The problem remains that FFAs
may be toxic only in an artiﬁcial in vitro environ-
ment. In conclusion, while lipotoxicity is a major
issue for the pathogenesis of insulin resistance in
various insulin target tissues, evidence that lipo-
toxicity and the lipid part of glucolipotoxicity con-
tribute to  cell secretory dysfunction or death in
human diabetes or animal models is presently weak
to nonexistent
Reduction of insulin content and abnormal
proinsulin secretion
 cells contain remarkable amounts of insulin,
about10%ofthetotalproteincontentwithanaver-
agecell,about20pgofinsulin.Insulinsynthesisis
balancedbyinsulinsecretionandbytheautophagic
destruction of secretory granules. Because insulin
mRNA has a long half-life and stable concentra-
tion,53 the ﬁne-tuning of replenishment after meals
seems mostly driven by glucose-stimulated transla-
tion. When  cells are exposed to the diabetic state,
they become degranulated such that in some exper-
imental systems the content per  cell mass can be
reduced to lower than 5% of normal.54 Data from
a variety of sources indicate that insulin depletion
is much more severe with high rather than modest
elevations in blood glucose. While secreted insulin
accounts for some of this depletion, the reduction
of insulin synthesis must be a critical component.55
Of secreted insulin immunoreactivity from 
cells, about 2–4% is proinsulin, while circulating
proinsulin in blood can be 10–40% of the total due
toitslongerhalf-life.Theproinsulintoinsulinratio
in blood is increased in T2D and to a lesser extent
IGT and has been used as a marker of  cell dys-
function. This proportional change is thought to
result from depletion of mature granules resulting
inincreasedsecretionoftheincompletelyprocessed
contents of immature granules.56
Five stages of diabetes; clinical
consequences of  cell dysfunction
induced by prediabetic and diabetic states
To understand both T1D and T2D, it is helpful
to conceptualize ﬁve stages in their progression
(Table 1).57 Stage 1 is successful compensation for
am o d e s tf a l li n cell mass in T1D or for insulin
resistance in T2D. The  cells secrete more insulin
to maintain a normoglycemic environment, which
in turn allows acute GSIS because  cells are not
exposed to glucotoxicity. With stage 2,  cell mass
drops a little more and/or insulin resistance wors-
ens, such that glucose levels rise to levels associated
with a marked loss of acute GSIS, which we postu-
late is caused by glucotoxicity. Stage 2 is equivalent
to impaired glucose tolerance (IGT) or IFG, which
is stable because of maintenance of meaningful
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Table 1. Five stages of diabetes57
Stage 1: Normal blood glucose levels: compensation for insulin resistance with increased  cell insulin secretion and
mass. With early autoimmune destruction of T1D, increased insulin secretion compensates for decreased  cell
mass.
Stage 2: Stable adaptation: IGT, IFG, pre-T1D, islet transplantation. Inadequate  cell mass allows modest
hyperglycemia, which leads to dysfunctional GSIS from glucotoxicity.
Stage 3: Unstable decompensation: T2D and early T1D; worsening glucotoxicity for  cells and insulin target tissues
causes a rapid rise in blood glucose levels.
Stage 4: Stable decompensation: higher blood glucose levels in T2D and early T1D, but enough insulin secretion to
control ketosis.
Stage 5: Decompensation: T1D; classic symptoms of diabetes and ketosis; severe reduction in  cell mass.
insulin secretion, such that only about 5% of indi-
v i d u a l sw i t hI G Tp r o g r e s st oT 2 Dp e ry e a r . 58 Stage
3isanunstablephaseinwhichincreasingglucotox-
icity produces more  cell dysfunction and insulin
resistance, leading to a rapid rise in glucose levels
to stage 4, with more serious hyperglycemia in the
rangeof9–17mM(160–300mg/dL).Thisrelatively
rapid deterioration in control may not be caused
by a fall in  cell mass but instead by increased
insulinresistancefromstressandovereating,forex-
ample. Evidence supporting the existence of stages
2–4 in humans was recently reported by the White-
hall study group.59 S t a g e5h a sm o r es e v e r e cell
depletion as found in T1D.
These concepts are therapeutically signiﬁcant for
T2D because aggressive treatment of subjects in
stage 4 may be able to reduce glucose levels to the
more stable stage 2 of IGT, or to an even better
stage1.Therearealreadysuggestionsthataggressive
early treatment of newly diagnosed patients with
T2D with stage 4 glucose levels may lead to last-
ing improvement in control.60 These stages are also
important for T1D because the  cell appears to
go through the same development of dysfunctional
insulin secretion as autoimmunity reduces  cell
mass.61 For example, subjects with new-onset T1D
may present with high glucose levels and then have
aremissionthatiseitherspontaneousorinducedby
immunosuppression.7 During remission C-peptide
levels might be considerably higher than when pa-
tients initially presented with hyperglycemia.62 De-
spite hopes that this could be explained by  cell
regeneration, relief from glucotoxicity leading to
improved  cell function seems like a better ex-
planation.
 cell birth and death
To understand changes in  cell mass one needs
to understand  cell turnover, which is better un-
derstood in rodents than in humans. Birth can re-
sult from replication of preexisting  cells or from
neogenesis, the formation of new islets thought
to originate from cells in the pancreatic duct ep-
ithelium. Evidence is accumulating that some cells
with duct identiﬁcation markers can serve as multi-
potent precursor cells.63,64 There has been debate
and even controversy about the relative roles of
replication versus neogenesis. Replication has been
shown to be particularly important in adult  cell
expansion65 and for regeneration after  cell de-
pletion from diphtheria toxin in mice.66 In fetal
life new islets are formed from cord- or duct-like
structures, and it is logical to think that postna-
tal neogenesis is largely a recapitulation of this
process. In spite of discordant lineage tracing re-
sults in mice,63 it is now better appreciated that
substantial neogenesis occurs during the neona-
tal period67,68 and in response to some forms of
injury.63,69,70
In humans the majority of  cell expansion oc-
curs in early childhood with probably a greater
contribution from replication than from neogen-
esis.71 In adults, some studies ﬁnd no evidence
of any  cell replication;72,73 however these ﬁnd-
ings are not straightforward. For example, when
adult human islets are transplanted into immuno-
incompetent mice, they always have Ki67+  cells
in the range of 0.2–0.7%.74 Perhaps there is some-
thing about the mouse in vivo environment that
turnsonquiescentcells.Itmaybesigniﬁcantthatal-
mostallstudieshaveusedpancreasesobtainedfrom
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Figure 4. Sectionofpancreas(20×magniﬁcation)stainedforinsulin.Numerouspancreaticductsareshown,withinsulin-positive
cells present in and next to duct wall, suggesting new islet formation from exocrine ducts (neogenesis). Figure taken from Ref. 2,
with permission from the American Diabetes Association.
autopsies or cadaver donors, which raises questions
as to whether the warm and cold ischemia of these
conditions dampens the Ki67 expression. This is
supported by the ﬁnding that in pancreatic samples
obtained at surgery Ki67 positivity was found to be
in the range of 0.5%.75
There appears to be a low rate of  cell death, as
judged by such techniques as TUNEL.2 Because 
cell mass is reasonably well maintained in nondia-
betics, it makes sense that there would be some low
levelof turnover, withbirth balancingdeath. Deter-
mining the contribution of neogenesis in humans
is very difﬁcult, but the presence of small clusters
ofinsulin-containingcellswithin,protrudingfrom,
and near ducts (Fig. 4), and the discovery of cells
double stained for insulin and the duct marker cy-
tokeratin, are consistent with some level of neo-
geneic activity.63 T h es e v e r eh y p o g l y c e m i as o m e -
times seen after bariatric surgery is associated with
pancreatic pathology consistent with neogenesis.76
There is speculation that this is driven by the very
highplasmalevelsofGLP-1seeninthesepatients.77
Regardless of how  cells are born, they are cer-
tainly long-lived; this is supported by the ﬁnding
that a very high percentage of  cells in adult hu-
mans contain lipofuscin, which takes a long time to
accumulate.78
Thepossiblesigniﬁcanceofalowrateofturnover
should not be underestimated. If 0.5% of  cells are
Ki67+ and Ki67 positivity lasts for 12 hours,  cell
masscouldmorethandoubleinlessthanayear.The
changes in mass will of course also be inﬂuenced by
thevariablesofdeath(fromapoptosisandnecrosis)
and neogenesis, which are even harder to quantify.
What causes the reduction of  cell mass
in T2D?
Many conclude that the reduced  cell mass in T2D
reﬂects an increased rate of  cell death, but while
this must often be true, there may also be a  cell
birth problem. For example, T2D may result from
an intrauterine growth disturbance or genetic and
environmental forces that slow  cell replication or
neogenesis.
There is a lot of circumstantial evidence that the
prediabetic/diabetic state, or more speciﬁcally glu-
cotoxicity, leads to an increased rate of  cell death
from either apoptosis or necrosis. However, over-
work in the absence of increases in glucose levels
seems to be associated with reduced  cell mass.
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The observation by the Butler group that individu-
alswithIFG(stage2)have,onaverage,a40%reduc-
tion in  cell mass (Fig. 1)2 suggests that something
deleteriousoccursduringthecompensatorystage1.
We know that glucose can stimulate replication,30
and we can argue that it still has an effect in insulin
resistantstateswhenglucoselevelsappeartobenor-
mal, as in stage 1. We hypothesize that during this
stage of compensation there is increased replication
of  cells, and suspect that there is some limitation
in the capacity for regeneration through glucose-
driven replication leading to slowing of birth. Thus,
duringthistimeofoverworkalimitationinthebirth
o fn e wc e l l sc o u l dl e a dt oa no l d e rp o p u l a t i o no f
cellsthathasahigherrateofcelldeath,whichcould
contributetotheimpressivereductionincellmass
found in the earliest stages of diabetes of IGT and
IFG,andcouldhelp explain theincreasedincidence
of apoptosis later in the disease.
W h i l ei n v e s t i g a t o r sm a ya d v o c a t ef o rt h ed o m i -
nance of their favorite mechanism, it may be best
to take the position that several mechanisms might
contribute.
Oxidative stress
There has been great interest in the possibility that
glucotoxicity leads to oxidative stress, which then
causes secretory dysfunction and an increased rate
ofcelldeath.79 Certainlyglucosestimulationleads
to an increase in reactive oxygen species (ROS),
but this is not necessarily bad. There is interest-
ing research underway to sort out the contributions
of ROS to important  cell signaling mechanisms
that are part of normal  cell function and to 
cell dysfunction and death.80 This has led to the
hope that antioxidant treatment might slow the ad-
verse processes.81 Indeed, the administration of N-
acetyl-cysteine has been found to slow the adverse
effectsofROSontheprogressionofdiabetesinZDF
rats.82
Amyloid
Theﬁrstdescriptionofamyloiddeposits,calledhya-
line at the time, in the islets of people with diabetes
was reported in 1900.83 It took until 1987 to de-
termine that this amyloid was formed from the 
cell secretory product islet associated polypeptide
(IAPP),84 which in humans and a few other species
canformthe-pleatedsheetsthatmakeupamyloid.
The question as to whether amyloid deposits are
just innocent bystanders or whether its formation
somehow contributes to cell death appears to have
been answered. Examination of pancreases from
subjects with T2D indicated that islets with large
amyloid deposits often have fewer  cells.85 When
human IAPP, which can form amyloid unlike ro-
dent IAPP, is overexpressed in  cells of mice or
rats, the result is worsening of diabetes associated
with more amyloid deposition.86–88 It now appears
that the toxicity is exerted not by the extracellular
deposits but by small ﬁbrils or toxic oligomers that
candamagecellmembranes.89,90 Thereisincreasing
evidence that these can cause damage while inside
the  cell; they may when outside as well. It is still
puzzling that amyloid deposits are seen in islets of
T2D and in insulinomas but are far less common in
obesity, in spite of the increased secretion of both
insulin and IAPP.
Endoplasmic reticulum stress
The potential contribution of endoplasmic retic-
ulum (ER) stress to  cell apoptosis in T2D has
received much attention in the past few years.91–93
ER stress is part of the unfolded protein response
(UPR). This UPR is turned on when the cell has
problemswiththecomplexprocessoffoldingnewly
synthesized proteins. To protect the cells, it recruits
chaperone proteins that help with folding, acceler-
ates the degradation of unfolded proteins, and in-
hibits the synthesis of new proteins. While the UPR
has important beneﬁts for function and survival, a
fully turned on stress response activates apoptotic
pathwaysthroughsuchmediatorsasC/EBPhomol-
ogousprotein(CHOP)andc-JunN-terminalkinase
(JNK). A study of gene expression in human  cells
transplanted into mice showed that these cells, in
a transplant site exposed to mild hyperglycemia,
had an activated UPR but reduced expression of
JNK and CHOP,94 suggesting that ER stress is more
helpful than harmful in that situation. In our study
of pancreases from cadaver donors with T2D, gene
expression was performed on laser-captured  cell-
enriched tissue with little change in ER stress genes,
although there were a few changes suggesting that
parts of the UPR were activated.95
Butler’s group stained for CHOP in pancreases
from subjects with T2D, and from lean and obese
subjects without diabetes.96 The  cells of both the
T2D and obese individuals had cytoplasmic CHOP
staining in about 15–20% of their  cells. However,
nuclear staining forCHOP wasseen in less than1%
Ann. N.Y. Acad. Sci. 1281 (2013) 92–105 c  2013 New York Academy of Sciences. 99Islet  cell mass in diabetes Weir & Bonner-Weir
of the  cell from T2D, and nuclear staining in the
obesesubjectswasevenlower.Thisisconsistentwith
the view that only small numbers of  cells in T2D
are dying at any one time, but that a larger num-
ber are showing signs of stress or fragility. Thus, the
few cells with nuclear CHOP could be on their way
to death while those with cytoplasmic CHOP may
be more vulnerable but still functional. Likewise, it
maybethatinT2Dmany cellshavesomeUPRac-
tivation, which protects them, but in a more fragile,
perhaps older, population of  cells, the proapop-
t o t i cE Rs t r e s sp a t h w a y sa r em o r ea c t i v e .
β cell dedifferentiation
Geneexpressionincellsexposedtohyperglycemia
canbestudiedaftersurgicalreductionofcellmass
in rats with partial pancreatectomy.29,50,97–99 After
various periods of time, the  cells in isolated islets
andintissuesectionsfromtheremnantpancreascan
be studied. Impressive changes in gene expression
were found in  cells exposed to either very modest
orseverehyperglycemia.Thesechangesincludedre-
duced expression of several key  cell transcription
factors, changes related to glucose metabolism, and
upregulation of genes related to stress. It has been
temptingtocallthischangeincellphenotypeded-
ifferentiation, but it is not possible to say that these
cells reverted to a phenotype that occurred earlier
in development. While it makes sense that some of
these changes could have a deleterious effect on se-
cretion, little can be said about how they might be
related to a fall in  cell mass.
A new look at phenotypic change was taken by
the Accili group, which obtained data from mice
lacking FoxO1 and suggested the novel hypothesis
that in T2D  cells are dedifferentiated to a state
of immaturity whereby they express neurogenin3,
Oct4, Nanog, and L-Myc and no longer make in-
sulin.100 Some of these cells even adopted an  cell
fate. The argument was made that restoration of
differentiation in these cells may be a therapeutic
path to increase - c e l lm a s si nT 2 D .T h i sw o r kw i l l
no doubt stimulate new research, but at this early
stagequestionsmustberaisedastowhetheraFoxO1
deﬁciencymodelisrelevanttoT2D.Certainlyinves-
tigators will take a closer look at human pancreatic
T2D islets for immature cells. The possible conver-
sionof cells to cellsisinterestingbutcell mass
in human T2D has not been found to be increased
in two thorough studies.1,101
Need to better characterize  cells to
understand pathogenesis
Most of our understanding comes from studying
largenumbersofisletcells,butmuchmorecouldbe
learned about pathogenesis if we could learn more
about the heterogeneity of  cell death. For exam-
ple, why is it that only one in many hundred cells is
chosentoenterthecellcycleandreplicate?Likewise,
what is special about the one cell of many that dies?
We know from many studies there is considerable
heterogeneity for the capacity to secrete insulin. A
human  cell may have a lifetime of a several years,
so there must be differences among cells that are
new, in the early stages of maturation, in midlife,
in the stage of postmitotic senescence, when they
are old and fragile, and ﬁnally when they are dy-
ing. Also, what are the differences between a new
 cell formed by neogenesis in a fetus versus one
that formed during adulthood? And, what are the
differences between  cells formed from neogenesis
comparedwiththoseproducedfromthereplication
of existing cells? How important is topical location,
suchastheislet centerornext tothemantle ofnon-
 cells? Could there be different fetal pathways of
development the lead to the generation of different
kinds of  cells? What might the differences be be-
tween cellsinthedorsalversustheventrallobesof
the pancreas? What happens to  cells in islets that
arelessactiveandhavelessbloodﬂow?102Onemight
guess that there is temporal cycling of  cells that
allows them to rest until needed. Surely the differ-
ences described above are accompanied by changes
in gene and protein expression, so there must be
ways to ﬁnd markers for many of the different 
cell types. Flow cytometry and histochemical stain-
ing may be the most promising ways to isolate these
different cell types for study. Even if only some of
these possibilities are realized, it is exciting to think
of how much might be learned about how  cells
function, are born, and die.
Restoration of  cell mass in diabetes
We know that restoration of  cell mass can
n o r m a l i z eb l o o dg l u c o s el e v e l si nb o t hT 1 Da n d
T2D. The proof-of-principle has been established
with islet transplantation in T1D103 and pancreas
transplantation for T2D.104 Unfortunately current
approaches require cadaver pancreases and im-
munosuppression, which greatly limits the number
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of diabetics that can be treated. To make  cell
replacement therapy more accessible, we need an
abundant supply of well-characterized  cells and
must ﬁnd safe ways to prevent autoimmune and
allogeneic killing of the newly provided  cells.
Possibilities for replacement include cellular trans-
plantationandregenerationofpancreaticendocrine
cells.
For a source of transplantable cells, islet cells de-
rived from human embryonic stem cells or induced
pluripotent stem (IPS) cells are particularly attrac-
tive because there have been impressive scientiﬁc
advances in recent years.105–107 Another hope is to
ﬁnd ways to expand human pancreatic cells in vitro
sotheycanbetransplanted.Thereareafewencour-
aging studies suggesting that  cells or pancreatic
duct cells can be directed to a mesenchymal pheno-
type, allowing expansion and then redifferentiation
to islet cells.108,109 The possibility of stimulating 
cell replication has also been receiving considerable
attention,withtheidentiﬁcationofnewcompounds
that can stimulate division110,111 and the elucida-
tion of mechanisms that might be exploited in the
future.112–116 Another approach is to create a  cell
linewithgeneticengineeringthatcanberedifferen-
tiatedbeforetransplantation,butsafetyconcernsare
likely to remain.117 Finally, the possibility of xeno-
transplantation with porcine islets from adult or
perinatal pigs continues to be explored.118,119
Finding ways to limit autoimmunity and allore-
jection has been a daunting endeavor. With stem
cells,itshouldbepossibletouselinesthatwillallow
favorable human leukocyte antigen (HLA) match-
ing. Transplantation of islet cells derived from iPS
cells generated from people with T2D should face
no immune attack, but those derived from subjects
with T1D should face a strong autoimmune reac-
tion. There are many approaches to control allo-
and autoreactivity that are beyond the scope of this
review, but the possibility of protecting cells with
immunobarriermembranesisreceivingrenewedat-
tention.120 It seems likely that the ﬁrst transplants
of islet cells derived from stem cells will employ this
protection method. The general approach is to use
eithermacroencapsulation,inwhichmanyisletsare
contained within a device often called a bioartiﬁcial
pancreas, or microencapsulation, in which a small
number of islets or cell aggregates are contained in
smallhydrogelcapsulesthatcouldbe400–1500m
in diameter. Islet cells can also be protected with
conformal coating using polyethylene glycol (PEG)
or similar materials.121
Finally,thereisthedreamofstimulatingregener-
ation of  cells in the pancreas.122 Drugs might be
developed that could stimulate  cell replication or
neogenesis. Another possibility is that the exocrine
pancreas, or possibly even cells in the liver, could
be reprogrammed to become  cells.123 In a strik-
ing example of reprogramming, a single injection
of adenoviruses carrying genes for three transcrip-
tionfactorsimportantforcelldevelopment(Pdx1,
neurogenin3,andMafA)intoamousepancreascan
produce large numbers of cells with  cell charac-
teristics that can store and release enough insulin to
reverse the diabetic state.124
Summary
Reduction of  cell mass is fundamental to the
pathogenesis of both T1D and T2D and leads to
severe dysfunction of insulin secretion. These two
abnormalities lead to the concept of the reduced 
cell functional mass. We need to know more about
how reduced mass results from unbalanced  cell
turnover,andunderstandhowthisleadstosecretory
dysfunction. Diabetes can be prevented or reversed
by inhibiting the fall of  cell mass or by restor-
ing mass through regeneration or transplantation.
Theseissuesareamongthehighestprioritiesforthe
ﬁeld.
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